Latest Conference Articles

Prespecified analysis of STEP-HFpEF trial shows semaglutide benefits consistent across ejection fraction spectrum, offering potential HFpEF management.

Hosts are joined by Marat Fudim, MD, MHS, of Duke, to discuss the REBALANCE-HF trial, which examined endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction.

DELTA-HF trial: Device-based thoracic duct decompression with the eLym system could prove beneficial in acute decompensated heart failure patients.

Slight differences in disease presentation, as well as navigating the safety discussion with parents, presents unique recommendations for pediatricians initiating invasive imaging.

The REBALANCE-HF trial at HFSA 2023 reveals that right greater splanchnic nerve ablation was well-tolerated and safe in patients with HFpEF, with additional analysis shedding light on the proportion of responders to the procedure.

Data show how care providers shifted their mindsets to prioritize efficacy, safety, tolerability and availability factors during the 2022 formula supply shortage and recall crises.

The optimization of diet and nutrition support during pediatric patients’ rehabilitation is a strategy in lieu of a comprehensively ideal guideline and requires an appreciation for the individual.

Maralixibat and odevixibat have been "game changers" for their benefit in pruritus, and clinicians are interested to learn more about their long-term hepatic benefit.

New data show a promising machine learning tool could help specialists detect fistula risks and provide more tailored, timely care in children.

Specialists are hindered by limited therapies and a lack of noninvasive testing methods. Martinez shares a wishlist for her colleagues.

Anand Shah, MD, MBA, provides insights into a study he led examining the impact of out-of-pocket costs and insurance type on uptake of GDMT in patients with heart failure with reduced ejection fraction.

A propensity score-matched analysis of data suggests use of spironolactone could reduce the 3-year risk of developing Alzheimer disease or dementia among patients with heart failure with reduced ejection fraction.

Data from the phase 3 PEDFIC trial program show the IBAT inhibitor benefits bile acid levels as well as itch and sleep issues among children with varying types of PFIC.

The features of pediatric IBD can be non-specific, but there are signs in biopsies and clinical history that may indicate what is and isn't IBD.

José López, MD, discusses the results of a study he led examining contemporary trends in racial disparities as it pertains to LVAD utilization in patients with heart failure with reduced ejection fraction.

An analysis of age-stratified fatty liver disease patient demographics show a surprising shift in racial/ethnic and sex trends among children and adolescents.

Lauren Eyadiel, MMS, PA-C, offers insight into a presentation from HFSA 2023 examining strategies for overcoming financial barriers to GDMT optimization in heart failure.

Major advances to biomarkers, targeted therapies and a modernized care team could help IBD specialists achieve a more nuanced care strategy for children.

Though a regimen of steroids and immunosuppressants are well proven, alternative options may be necessary.

New research suggests multiple antibiotic courses may influence levels of the protein zonulin—which in part may indicate a higher risk of celiac disease.

Particularly in children, it's critical that referring physicians keep an awareness for clear symptoms and signs of autoimmune liver disease.

An interview regarding the current impacts of environmental health on food availability, nutrition, and more.

An institution's review of prescriptions in the first year since dupilumab's historic FDA approval for eosinopihlic esophagitis shows patients waited a mean 46 days to initiate the biologic therapy.

Stephen Greene, MD, discusses trials, data, and themes to look for at the HFSA 2023 meeting.

A new study seeks to compare the outcomes of biopsies among American children at risk of celiac disease, with European thresholds that would deem such biopsies unnecessary.

Findings from the pivotal phase 3 trial that which supported linaclotide's FDA approval show significant benefit in bowel movement and stool consistency.

The author of the largest clinical trial for pediatric PFIC to date discusses the various benefit maralixibat provides to disease managementr.

A new review and analysis suggests a combination treatment regimen for children in acute liver failure due to autoimmune hepatitis may help them maintain native liver survival.